In Vivo MR Techniques in Drug Discovery and Development

Imaging technologies are receiving much attention in the pharmaceutical industry because of their potential for accelerating drug discovery and development. Magnetic Resonance Imaging (MRI) is one of the principal imaging modalities because it allows information to be gathered non-invasively. The non-invasiveness of MR strengthens the link between preclinical and clinical pharmaceutical research, contributing to improve the characterization of compound effects in early stages of the discovery process in order to increase the chances of success in later phases of drug development. Edited by a leading researcher in MR technology, with contributions from foremost experts in academia and the pharmaceutical industry, this title illustrates the use of MR techniques throughout the drug discovery and development process, from target identification and validation to clinical studies. Numerous chapters focus on individual disease areas, including neurological, cardiac, and pulmonary disorders, cancer studies, diabetes, arthritis, solid organ transplantation, and stem cell-based therapies, showing that different imaging solutions are needed for specific organs. human embolic stroke, conventional lung function tests, mouse hive, choline phospholipid metabolism, molecular imaging applications, imaging readouts, amphetamine stimulus, dopamine cell loss, imaging biomarkers, molecular weight contrast agents, mouse imaging, bone attrition, intramyocellular lipid content, synovial volume, synovial enhancement, parenchymal signal, mixed meal ingestion, cartilage signal, cartilage volume, focal cerebral ischemia models, living renal donors, total choline, relative cerebral blood volume, hepatic glycogen metabolism, forepaw stimulation